PDSB
Income statement / Annual
Last year (2024), PDS Biotechnology Corporation's total revenue was $0.00,
and the percentage change from the previous year is not available.
In 2024, PDS Biotechnology Corporation's net income was -$39.35 B.
See PDS Biotechnology Corporation,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2024
|
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
| Period Ended |
12/31/2024 |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
12/31/2015 |
| Operating Revenue |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
| Cost of Revenue |
$0.00
|
$57,326.00
|
$49,078.00
|
$246,388.00
|
$176,292.00
|
$98,414.00
|
$69,118.00
|
$182,918.00
|
$100,117.00
|
$53,116.00
|
| Gross Profit |
$0.00
|
-$57,326.00
|
-$49,078.00
|
-$246,388.00
|
-$176,292.00
|
-$98,414.00
|
-$69,118.00
|
-$182,918.00
|
-$100,117.00
|
-$53,116.00
|
| Gross Profit Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Research and Development Expenses |
$22.57 B
|
$27.76 M
|
$29.43 M
|
$11.25 M
|
$7.92 M
|
$6.10 M
|
$16.07 M
|
$34.31 M
|
$24.83 M
|
$17.84 M
|
| General & Administrative Expenses |
$13.76 B
|
$15.02 M
|
$12.24 M
|
$10.18 M
|
$6.96 M
|
$10.98 M
|
$14.29 M
|
$17.65 M
|
$14.69 M
|
$8.66 M
|
| Selling & Marketing Expenses |
$0.00
|
$264,000.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General & Administrative Expenses |
$13.76 B
|
$15.28 M
|
$12.24 M
|
$10.18 M
|
$6.96 M
|
$10.98 M
|
$14.29 M
|
$17.65 M
|
$14.69 M
|
$8.66 M
|
| Other Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$15,608.00
|
$3.95 B
|
$12.74 B
|
$0.00
|
-$163,463.00
|
-$1.88 M
|
| Operating Expenses |
$36.26 M
|
$43.05 M
|
$41.67 M
|
$21.44 M
|
$14.90 M
|
$17.08 M
|
$30.36 M
|
$51.97 M
|
$39.51 M
|
$26.50 M
|
| Cost And Expenses |
$0.00
|
$43.05 M
|
$41.67 M
|
$21.44 M
|
$14.90 M
|
$17.08 M
|
$30.36 M
|
$51.97 M
|
$39.51 M
|
$26.50 M
|
| Interest Income |
$2.51 B
|
$2.90 M
|
$935,180.00
|
$4,346.00
|
$55,006.00
|
$353,490.00
|
$871,879.00
|
$700,903.00
|
$212,299.00
|
$9,084.00
|
| Interest Expense |
-$4.67 B
|
$4.21 M
|
$1.32 M
|
$0.00
|
$0.00
|
$33,559.00
|
$1.43 M
|
$2.18 M
|
$1.20 M
|
$816,494.00
|
| Depreciation & Amortization |
$6.83 B
|
$57,326.00
|
$49,078.00
|
$246,388.00
|
$176,292.00
|
$98,414.00
|
$69,118.00
|
$182,918.00
|
$100,117.00
|
$53,116.00
|
| EBITDA |
-$36.32 B |
-$40.08 M |
-$41.62 M |
-$21.19 M |
-$14.67 M |
-$7.25 M |
-$3.58 M |
-$51.08 M |
-$39.36 M |
-$28.32 M |
| EBITDA Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Operating Income Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Total Other Income/Expenses Net |
-$2.16 B
|
-$1.30 M
|
-$381,339.00
|
$4,346.00
|
$55,006.00
|
$13.65 M
|
-$190,295.00
|
-$50.03 M
|
-$36.45 M
|
-$2.69 M
|
| Income Before Tax |
-$38.48 B
|
-$44.35 M
|
-$42.05 M
|
-$21.43 M
|
-$14.85 M
|
-$7.38 M
|
-$43.65 M
|
-$53.45 M
|
-$40.67 M
|
-$29.19 M
|
| Income Before Tax Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Income Tax Expense |
$869.17 M
|
-$1.41 M
|
-$1.20 M
|
-$4.52 M
|
-$135,683.00
|
-$381,513.00
|
-$2.78 M
|
-$2.59 M
|
-$1.85 M
|
-$1.11 M
|
| Net Income |
-$39.35 B
|
-$42.94 M
|
-$40.85 M
|
-$16.92 M
|
-$14.85 M
|
-$7.00 M
|
-$40.87 M
|
-$50.86 M
|
-$38.82 M
|
-$28.08 M
|
| Net Income Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| EPS |
-1079.45 |
-1.39 |
-1.43 |
-0.66 |
-0.89 |
-1.44 |
-26.16 |
-33.47 |
-26.9 |
-69.43 |
| EPS Diluted |
-1079.45 |
-1.39 |
-1.43 |
-0.66 |
-0.89 |
-1.44 |
-26.16 |
-33.47 |
-26.9 |
-69.43 |
| Weighted Average Shares Out |
$36.45 M
|
$30.95 M
|
$28.60 M
|
$25.60 M
|
$16.75 M
|
$4.87 M
|
$1.56 M
|
$1.52 M
|
$1.44 M
|
$404,396.00
|
| Weighted Average Shares Out Diluted |
$36.45 M
|
$30.95 M
|
$28.60 M
|
$25.60 M
|
$16.75 M
|
$4.87 M
|
$1.56 M
|
$1.52 M
|
$1.44 M
|
$404,396.00
|
| Link |
|
|
|
|
|
|
|
|
|
|
